A5037708178- RNA modifications and cancer
- Lung Cancer Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Esophageal Cancer Research and Treatment
- Photodynamic Therapy Research Studies
- Epigenetics and DNA Methylation
- Cardiac, Anesthesia and Surgical Outcomes
- Lung Cancer Treatments and Mutations
- MicroRNA in disease regulation
- Eosinophilic Esophagitis
- Neonatal Respiratory Health Research
- Genomic variations and chromosomal abnormalities
- Pneumocystis jirovecii pneumonia detection and treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Esophageal and GI Pathology
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Nanoplatforms for cancer theranostics
- Pediatric health and respiratory diseases
- Lung Cancer Research Studies
- COVID-19 and healthcare impacts
- Tracheal and airway disorders
- HIV-related health complications and treatments
- Pancreatic and Hepatic Oncology Research
University of British Columbia
2014-2025
BC Cancer Agency
2010-2025
Norfolk and Norwich University Hospital
2017-2023
University of East Anglia
2017-2023
Norfolk and Norwich University Hospitals NHS Foundation Trust
2018-2023
University of Toronto
1982-2023
St. Paul's Hospital
2021-2023
St. Paul's Hospital
2023
Faculty (United Kingdom)
2022
Laboratoire des Sciences de l'Ingénieur, de l'Informatique et de l'Imagerie
2020-2021
Background Activating mutations in one allele of an oncogene (heterozygous mutations) are widely believed to be sufficient for tumorigenesis. However, mutant specific imbalance (MASI) has been observed tumors and cell lines harboring oncogenes. Methodology/Principal Findings We determined 1) mutational status, 2) copy number gains (CNGs) 3) relative ratio between wild type alleles KRAS, BRAF, PIK3CA EGFR genes by direct sequencing quantitative PCR assay over 400 human tumors, lines,...
Somatic mutations and copy number alterations (as a result of deletion or amplification large portions chromosome) are major drivers human lung cancers. Detailed analysis cancer–associated chromosomal amplifications could identify novel oncogenes. By performing an integrative cytogenetic gene expression non–small-cell cancer (NSCLC) small-cell (SCLC) cell lines tumors, we report here the identification frequently recurring at chromosome 11 band p13. Within this region, only TNF...
Objective: Volatile organic compounds (VOCs) in exhaled breath as measured by electronic nose (e-nose) have utility biomarkers to detect subjects at risk of having lung cancer a screening setting. We hypothesize that analysis using an e-nose chemo-resistive sensor array could be used tool discriminate patients diagnosed with from high-risk smokers. Methods: Breath samples 191 subjects-25 and 166 smoker control without cancer-were analyzed. For clinical relevancy, both groups were matched for...
Chromosomal regions harboring tumor suppressors and oncogenes are often deleted or amplified. Array comparative genomic hybridization detects segmental DNA copy number alterations in relative to a normal control. The recent development of bacterial artificial chromosome array, which spans the human genome tiling path manner with >32,000 clones, has facilitated whole profiling at an unprecedented resolution. Using this technology, we comprehensively describe compare genomes 28 commonly used...
Background Traditionally, non-small cell lung cancer is treated as a single disease entity in terms of systemic therapy. Emerging evidence suggests the major subtypes—adenocarcinoma (AC) and squamous carcinoma (SqCC)—respond differently to Identification molecular differences between these tumor types will have significant impact designing novel therapies that can improve treatment outcome. Methods Findings We used an integrative genomics approach, combing high-resolution comparative genomic...
Small cell lung cancer (SCLC) is a highly aggressive neoplasm with extremely poor clinical outcomes and no approved targeted treatments. To elucidate the mechanisms responsible for driving SCLC phenotype in hopes of revealing novel therapeutic targets, we studied copy number methylation profiles SCLC. We found disruption E2F/Rb pathway was prominent feature deregulated 96% samples investigated strongly associated increased expression EZH2, an oncogene core member polycomb repressive complex...
Abstract Gene function in cancer is often cell type-specific. The epithelial cell-specific transcription factor ELF3 a documented tumor suppressor many tumors yet displays oncogenic properties others. Here, we show that an oncogene the adenocarcinoma subtype of lung (LUAD), providing genetic, functional, and clinical evidence specificity. We discover region focal amplification at chromosome 1q32.1 encompassing locus LUAD which absent squamous subtype. dosage promoter hypomethylation affect...
Lung cancer is the most common cause of cancer-related deaths. Tobacco smoke exposure strongest aetiological factor associated with lung cancer. In this study, using serial analysis gene expression (SAGE), we comprehensively examined effect active smoking by comparing transcriptomes clinical specimens obtained from current, former and never smokers, identified genes showing both reversible irreversible changes upon cessation. Twenty-four SAGE profiles bronchial epithelium eight twelve four...
Purpose: Breath analysis has a potential prospect to benefit the medical field based on its perceived advantages become point‐of‐care, easy use, and cost‐effective technology. Early studies done by mass spectrometry show that volatile organic compounds from human breath can represent certain disease states of our bodies, such as lung cancer, revealed analysis. But is costly slow‐turnaround time. The authors’ goal develop more portable cost effective device Raman spectroscopy hollow...
Rationale: Age-related diseases like chronic obstructive pulmonary disease (COPD) occur at higher rates in people living with human immunodeficiency virus (PLWH) than uninfected populations. Objectives: To identify whether accelerated aging can be observed the airways of PLWH COPD, manifest by a unique DNA methylation signature. Methods: Bronchial epithelial brushings from and without COPD HIV-uninfected adults (N = 76) were profiled for gene expression. We evaluated global Alu LINE-1...
Cigarette smoke is associated with the majority of lung cancers: however, 25% cancer patients are non-smokers, and half all newly diagnosed former smokers. Lung tumors exhibit distinct epidemiological, clinical, pathological, molecular features depending on smoking status, suggesting divergent mechanisms underlie tumorigenesis in smokers non-smokers. MicroRNAs (miRNAs) integral contributors to mediate biological responses smoking. Based hypothesis that smoking-specific miRNA differences...
Non-small-cell lung cancer (NSCLC) is an aggressive, highly chemoresistant disease. Reliable prognostic assays and more effective treatments are critically required. BIRC6 (baculoviral inhibitors of apoptosis proteins repeat-containing 6) protein a member the family thought to play important role in progression or chemoresistance many cancers. In this study, we investigated whether expression can be used as marker potential therapeutic target for NSCLC.In retrospective analysis, was...
Background: Patient education is a key component in the management of chronic obstructive pulmonary disease (COPD). Delivering effective to ethnic groups with COPD challenge. The objective this study was develop and assess effectiveness culturally linguistically specific audiovisual educational materials supporting self-management practices Mandarin- Cantonese-speaking patients. Methods: Educational were developed using participatory approach (patients involved development pilot test...
Rationale: Inhaled corticosteroids (ICS) are commonly prescribed with long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease (COPD). To date, the effects of ICS therapy on airway microbiome COPD unknown. Objectives: determine ICS/LABA patients COPD. Methods: Clinically stable were enrolled into a 4-week run-in period during which was discontinued and all participants placed formoterol (Form) 12 μg twice daily (BID). The then randomized to budesonide/formoterol (Bud + Form;...